News About: Pharm. Industry
Daewoong releases orally disintegrating tablet, Harunosin D (tamsulosin) tablet
Daewoong Pharm announced on March 2 that it has marketed Harunosin D (tamsulosin) tablet, a dosage form for the treatment for functional symptoms of benign prostatic hyperplasia (BPH) in Korea.
Harunosin D tablet c...
Bayer Healthcare boosts Levita 10 mg sales
Bayer Healthcare boosts Levita 10 mg sales
Multinational pharmaceutical companies are stepping up their marketing in the erectile-dysfunction treatment drug market in Korea, which is forecast to become competitive,...
KPMA appoints acting president
The Korea Pharmaceutical Manufacturers Association said on February 25 it has nominated Yoon Suk-geun, incumbent president of Ilsung Pharm, as the acting KPMA chairman.
Yoon is expected to deal with the drug relate...
Sales of weight loss pill sibutramine unlikely to be banned
The controversial anti-obesity drug sibutramine will not be banned in Korea, reports said.
In a recent forum, the Korea Food and Drug Administration Director Yoo Moo-young said that the drug agency’s review showed ...
Health insurance to expand coverage to Glivec
The costs that individuals will have to shoulder for treatment of Gastrointestinal Stromal Tumors (GISTs) will go down from March 1 thanks to the government’s plan to expand the national health insurance coverage for ...
JAMA officials visit Korea
A total of 12 officials from the Japanese Pharmaceutical Manufacturers Association (JPMA) and 13 journalists in Japan, including Yomiuri Shinbun, Asahi Shinbun and Tokyo Broadcasting, made their visit to Asan Medical ...
More M&As essential for local pharmaceutical industry
The government needs to encourage mergers and acquisitions (M&As) among pharmaceutical firms in order to make them more productive and profitable, according to an executive of Samsung Electronics.
In a local forum ...
Samil, Boehringer Ingelheim strengthens strategic alliance
Samil Pharm said it has joined hands with Boehringer Ingelheim Korea to market Mirapex (pramipexole), a medication indicated for treating early-stage Parkinson’s disease and restless legs syndrome (RLS)
Samil has r...
Novartis expands capabilities to execute multinational trials in Korea
Global pharmaceutical giant Novartis Inc. has launched a massive assault on the Korean growth market with its growing scientific reputation. Its clinical members hand-pick Korean doctors to lead local clinical tests.
...
Novartis Korea, Handok holds symposium for Galvusmet
Novartis Korea and Handok Pharm said on February 20 that it has held a launching symposium for Galvusmet, a combination drug consisting of 850–1000 mg metformin and 50 mg of the DPP-4 inhibitor vildagliptin, while Gal...
